Published in Cancer Weekly, February 8th, 2005
Under the terms of the agreement, TaiGen will be responsible for conducting phase 1b and phase 2 development of the compound to meet worldwide regulatory standards.
If phase 2 results are positive, Procter & Gamble, in conjunction with TaiGen, may then seek a pharmaceutical partner for the phase 3 development and subsequent commercialization of the compound.
In addition, TaiGen acquires development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.